Timothy Matway, MD
Interventional Pain Medicine · Bloomfield Hills, MINPI 1306133434
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 271 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by Medtronic at 26.6% of the total. Reporting peaked in 2021 at $1,599 and has fallen 50.3% since, to $794 in 2025.
Across 271 payments — averaging $28.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Nevro Corp.$883
- Abbott$710
- Boston Scientific$498
- Nalu Medical, Inc.$483
- Collegium Pharmaceutical, Inc.$420
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,668100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 50 | $2,044 |
| Nevro Corp. | 27 | $883 |
| Abbott | 17 | $710 |
| Boston Scientific | 19 | $498 |
| Nalu Medical, Inc. | 15 | $483 |
| Collegium Pharmaceutical, Inc. | 22 | $420 |
| Scilex Pharmaceuticals Inc. | 16 | $369 |
| Vertos Medical, Inc. | 8 | $348 |
| AbbVie(2 entities) | 15 | $278 |
| Averitas Pharma Inc. | 7 | $185 |
| Novartis | 11 | $171 |
| Globus Medical | 9 | $167 |
| MML US, Inc. | 1 | $135 |
| Biodelivery Sciences International, Inc. | 8 | $109 |
| Pfizer | 6 | $105 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $83 |
| MDD US Operations, LLC | 6 | $79 |
| Amgen(2 entities) | 4 | $75 |
| Stryker | 1 | $61 |
| Si-bone, Inc. | 1 | $58 |
| Tersera Therapeutics LLC | 2 | $44 |
| Daiichi Sankyo Inc. | 2 | $41 |
| Curonix LLC | 1 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 3 | $38 |
| Kaleo, Inc. | 2 | $23 |
| Relievant Medsystems, Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Spinal Simplicity, LLC | 1 | $20 |
| Biotronik NRO, Inc. | 1 | $20 |
| Bioventus LLC | 1 | $19 |
| Eisai Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Redhill Biopharma Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| Virtus Pharmaceuticals LLC | 1 | $13 |
| GRT US Holding, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS$302
- Senza$279
- INCEPTIV$252
- Accurian$172
- Axium INS DRG IPG$161
- KYPHON EXPRESS II KYPHOPAK TRAY$146
- PROCLAIM$146
- Nalu Neurostimulation System$138
- ReActiv8$135
- Vanta$125
- INTELLIS ADAPTIVESTIM$124
- mild Device Kit$109
How this compares
$7,668 in reported general payments places this provider in the 75th percentile of 88 interventional pain medicine providers in Michigan.
See all interventional pain medicine providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine | 107 | $31,673 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,567 | $26,610 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 709 | $16,350 |
| Gabapentin | 957 | $11,460 |
| OxycontinOxycodone Hcl | 14 | $11,165 |
| Morphine Sulfate ErMorphine Sulfate | 332 | $8,185 |
| Fentanyl | 89 | $5,403 |
| Pregabalin | 370 | $4,393 |
| Xtampza ErOxycodone Myristate | 11 | $4,036 |
| Lidocaine | 25 | $3,140 |
| Oxycodone Hcl | 123 | $2,665 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 17 | $2,278 |
| Tramadol Hcl ErTramadol Hcl | 23 | $1,810 |
| Tizanidine Hcl | 214 | $1,767 |
| Baclofen | 128 | $1,732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $420 | $4,03611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 88 interventional pain medicine providers in Michigan.
Other interventional pain medicine in Bloomfield Hills
- Joshua GitlinBloomfield Hills$8K
- Ryan PollinaSaint Clair Shores$144K
- Ariel MajjhooMonroe$124K
- Chad BrummettAnn Arbor$109K
- Anand ThakurClinton Township$102K
- Evan PeskinFlint$72K
- Richard FerroLansing$31K
- John ChatasAnn Arbor$29K
- Bryant IttiaraAllen Park$28K
- Fadi DellyWyandotte$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.